LBPO.IM01 · 免疫学 · Late-Breaking

致癌性KRAS通过CD9重塑膜张力以清除细胞外肿瘤DNA从而抑制DNA感知

Oncogenic KRAS suppresses DNA sensing via CD9 by remodeling membrane tension to clear extracellular tumor DNA

海报缩略图:致癌性KRAS通过CD9重塑膜张力以清除细胞外肿瘤DNA从而抑制DNA感知
编号 LB084 展板 10 时间 4/19 02:00–05:00 区域 Section 54 主讲 Di Cao
分会场 Late-Breaking Research: Immunology 1
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Di Cao1, Weiyi Zhou2, Zhixiong Li1, Shixun Lu1, Zhenlin Hou1, Long Yu1, Yuanjun Guan3, Guoqiang Wang4, Yifan Liu1, Zhijie Huang1, Hao Wang1, Jingyi Dai1, Cong Li1, Jing Wang1, Gong Chen1

1Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China,2The Second Affiliated Hospital of Nanchang University, Nanchang, China,3Sun Yat-sen University, Guangzhou, China,4Burning Rock Biotech, Guangzhou, China

摘要 Abstract

中文摘要
控制细胞外肿瘤DNA(tDNA)丰度的机制仍不明确,而tDNA日益被认识到可调节固有免疫并可作为临床生物标志物的来源。在此,我们展示致癌性KRAS通过诱导四跨膜蛋白CD9来促进tDNA清除,CD9招募FXR1以重塑肌动蛋白皮层、降低质膜张力并促进细胞外tDNA的内吞摄取。tDNA的减少削弱了肿瘤相关巨噬细胞(TAM)中ZBP1依赖的DNA感知,使其转向免疫抑制状态。阻断CD9可恢复细胞外tDNA和DNA感知、重编程TAM,并在KRAS突变的癌症模型中与PD-1阻断协同作用。这些发现描绘了一条KRAS-CD9-FXR1通路,它将膜力学与细胞外DNA清除和免疫逃逸相偶联,为靶向CD9以增强检查点阻断疗效提供了有力依据。
查看英文原文 English abstract
The mechanisms controlling the extracellular abundance of tumor DNA (tDNA), which is increasingly recognized to modulate innate immunity and serves as a source of clinical biomarkers, remain poorly defined. Here, we show that oncogenic KRAS promotes tDNA clearance by inducing the tetraspanin CD9, which recruits FXR1 to remodel the actin cortex, lower plasma-membrane tension, and promote endocytic uptake of extracellular tDNA. This reduction in tDNA dampens ZBP1-dependent DNA sensing in tumor-associated macrophages (TAMs), shifting them toward an immunosuppressive state. Blockade of CD9 restores extracellular tDNA and DNA sensing, reprograms TAMs, and synergizes with PD-1 blockade in KRAS -mutant cancer models. These findings delineate a KRAS-CD9-FXR1 pathway that couples membrane mechanics to extracellular DNA clearance and immune evasion, providing a strong rationale for targeting CD9 to augment the efficacy of checkpoint blockade.
利益披露 Disclosure
D. Cao, None.. W. Zhou, None.. Z. Li, None.. S. Lu, None.. Z. Hou, None.. L. Yu, None.. Y. Guan, None.. G. Wang, None.. Y. Liu, None.. Z. Huang, None.. H. Wang, None.. J. Dai, None.. C. Li, None.. J. Wang, None.. G. Chen, None.

← 返回 AACR 2026 检索